Skip to main content
SpringerLink
Log in

Abciximab: unfavourable benefit-risk profile in ischaemic stroke

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Adams Jr HP, Effron MB, Torner J, Dávalos A, Frayne J, Teal P, Leclerc J, Oemar B, Padgett L, Barnathan ES, Hacke W, AbESTT-II Investigators.Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 39: 87-99, No. 1, Jan 2008

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abciximab: unfavourable benefit-risk profile in ischaemic stroke. React. Wkly. 1188, 4 (2008). https://doi.org/10.2165/00128415-200811880-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200811880-00009

Keywords

Search

Navigation